Вы находитесь на странице: 1из 23

| 

  

 
O By-
AAKASH DATTA
S-102
FYBMS.
x  
    

 
 
 

 

  




    
 


  


   



x
2 2
è |  Ind
y n Ind 
on of  
 
 nd o
 dvnd on  
dv opn on
.( I 
nkd 4 n
vo  
nd 11 n v  
ob y.)
è Fo
p  pn k 
o
op 
d
nbo
nd op  d opond

 o
 vy yp of d 
now d
nd no
y.(70% of   ony'
dnd 
by Indn p  nd
y)
è nd
y don y  d on ´v

n nn 
2 
è „ „ 
   
„ „
è „  „ „„„ 

 „ „
è
„„!
 „„  
"#
„ $„ÿ 
 

   
è %„ &'„ ( 
 „
 
è „ )   „*
 „
)
„ „ „„
è +,(-'.' /0*1*1+*23M 
 

  
À 

 
  

 
è u    
By sales India's largest pharma firm with the returns touching Rs
4,198.96 crore (Rs 41.989 billion) in 2007
è ©u    
ith a turnover of Rs 4,162.25 crore (Rs 41.622 billion) in
2007, Dr Reddy's lab is second largest drug firm in India by sales .
è º
 ºipla generated an annual revenue of Rs 3,763.72 crore (Rs 37.637 billion) in 2007
making itself the third largest pharmaceutical firms.
è {    
{un Pharma Industries had an overall earnings of Rs 2,463.59 crore
(Rs 24.635 billion) in 2007.
è  
   'upin 'abs yielded total profit of Rs 2,215.52 crore (Rs 22.155 billion) in 2007.
è M 
   India's sixth largest pharma company by sales, Aurobindo posted Rs
2,080.19 crore (Rs 20.801 billion) annual returns in 2007.
è â {

   ith 2007 turnover touching Rs 1,773.41 crore (Rs 17.734
billion, G{ is India's seventh largest pharma firm.
è º 
     ºadila's earnings was Rs 1,613.00 crore (Rs 16.13 billion) in the fiscal
year 2007, establishing itself as India's eight largest drug company.
è M 
  ith an annual revenue of Rs 983.80 crore (Rs 9.838 billion) in 2007,
Aventis Pharma has made a place for itself in the top ten pharma companies in India
è    
Ipca is India's 10th largest pharma company by sales and in 2007 it had a
turnover of Rs 980.44 crore (Rs 9.804 billion)
Π
  

 

è Baidyanath group
O Nicholas Piramal
è Biocon
O Panacea Biotec
è ºadila Healthcare
O Pharmaceuticals in India
è Dabur
O G. V. Prasad
è Dey's Medical
O RPG 'ife {ciences
è Hamdard (akf)
O {erum Institute of India
'aboratories
O {trides Arcolab
è Hetero Drugs
O TT Group
è Hindustan Antibiotics 'imited
O Torrent Pharmaceuticals
è Medisys Biotech
O ockhardt
è Nectar 'ifesciences
2 
 2
2  
       


 
 

O   
O     
O   

 
© 2 

3  
   
| 
 
  


 





 


 


 
   

 

 
 
!

 
 

 

 

 

 !
 

 

 
 "

| 

 

 
 "
#
  


 

$%
 
 



 



 
 &
 
 %

 

 


'|   %(
 
| 

+, -. 
/

* 
) 
|   
*  
0 

,
 ./*0,%
1 "2
{ À
{{
{uâ{

1. India with a population of over a billion is a a a 



  (In fact the penetration of modern medicine is less than 30% in
India.)

2. The  

aa in the country has resulted in fast


changing lifestyles in urban and to some extent rural centres.

o. Indian manufacturers are one of the a 




in the world.

.Indian pharmaceutical industry possesses aa 



  aa.
M{{
O  „ „ 
O $ „
O „ „„ „
„  
O +„„  „ „ *

    

 „„3
 „  4
   „  
„  5
Œ Œ

è À 

    
 
 
 
 

 

è 
    
  

  


 
  

  

  
    

è ! 

    
 
 
 
"    
  
   
# 
  #
è $
      
  %&'
  #  
(

  

 
   
      
 

è There are certain concerns over the patent regime regarding its
current structure. It might be possible that the new government
may change certain provisions of the patent act formulated by the
preceding government.

è Threats from other low cost countries like ºhina and Israel exist.
However, on the quality front, India is better placed relative to
ºhina. {o, differentiation in the contract manufacturing side may
wane.
|À{

{

2©
  22 

O 10,000 different players ÿ    


  a 

O entry barriers to pharmaceutical industry are very low.
O small players that are focussed on a particular region have a
better hang of the distribution channel, making it easier to
succeed
  22   


è   
     „ 
„ „
   „„   „
„ „„ 
è          
    

  

   
 
 
è 
 
 
 


   
  

     
 
  ŒŒ

è The suppliers have very low bargaining power and the
companies in the pharmaceutical industry can switch from
their suppliers without incurring a very high cost.
è {upplier can go for forward integration to become a
pharmaceutical company.(companies like Orchid ºhemicals
and {ashun ºhemicals were basically chemical companies
who turned themselves into pharmaceutical companies.)
{
À
À
è The capital requirement for the industry is very low; creating a
regional distribution network is easy, since the point of sales is
restricted in this industry in India.
è However, creating brand awareness and franchisee among
doctors is the key for long term survival.
è Also, quality regulations by the government may put some
hindrance for establishing new manufacturing operations.
è The new patent regime has raised the barriers to entry.
è But it is unlikely to discourage new entrants, as market for
generics will be as huge.
À  ÀŒÀÀÀ
è hatever happens, demand for pharmaceutical products
continues and the industry thrives.
è One of the key reasons for high competitiveness in the industry is
that as an ongoing concern, pharmaceutical industry seems to
have an infinite future.
è However, in recent times the advances made in thee field of
biotechnology, can prove to be a threat to the synthetic
pharmaceutical industry.
è Yoga and neuropathy

|À
{À
À
{

è marking presence globally and competing with the


pharmaceutical companies from the developed countries like
Europe, Japan, and United {tates
è generic drug sales to promote drug discovery projects and new
delivery technologies. ºontract research in India is also growing
at the rate of 20-25% per year and was valued at U{ 10-
120millio
è e can expect a significant level of consolidation- a major
portion of small players are likely to be wiped out
{{{

{
O J    M



O M   
   
O     

O 
 
O      
|
è ÔÔÔ  
è ÔÔÔ 

è ÔÔÔ  

è ÔÔÔ Ô 
 
è ÔÔÔ  
è ÔÔÔ 


 
è ÔÔÔ   
è ÔÔÔ
 



è ÔÔÔ  

è ÔÔÔ 

è ÔÔÔ   

è ÔÔÔ

 
è ÔÔÔ

 

À 


AA A{H DATTA
{-102
FYBM{